
301495827€ - -



HOWARD E MORGAN, M.D. Charles B. Degenstein Distinguished Scientist

June 29, 1990

Dr. William F. Raub, Acting Director National Institutes of Health Building 1, Room 126 Bethesda, MD 20892

Dear Dr. Raub,

I am writing on behalf of the Panel of Consultants Concerning Research Conducted in the Laboratory of Tumor Cell Biology, National Cancer Institute by Dr. Robert Gallo et al. The Panel met on June 27 with the following members in attendance: F.M. Richards (Chairman), J. Areen, A. Gilman, A.J. Levine, H.E. Morgan, M.J. Osborn, J.D. Stobo, and J. Sambrook. Dr. Richards is away for the next month and I am serving as Acting Chairman. The Inquiry Team consisting of J. Hallum, S. Hadley and P. Parkman presented a portion of their findings centered on the work of the laboratory in the period from April 1983 to August 1984. The Panel considered these findings and the 4 papers that were published in Science on 4 May 1984.

After considering a) the current status of the Inquiry, b) the internal NIH procedures and regulations, c) the significance of the change in status from an inquiry to a formal investigation of possible scientific misconduct, and d) the importance of public perception of NIH and Panel actions, the Panel voted unanimously to recommend the following action to you: termination of the inquiry phase of proceedings and insutution of the formal investigation. This decision was based on the review of material presented at the meeting. Some data appeared to be missing from the data books. There is a possibility of selection and/or misrepresentation of data. There is a need for the Panel to plan experiments on the viral samples that have been sequestered or that can be located. These

NIH FXEC SECLE AND TO

Dr. William Raub June 29, 1990 Page 2

experiments will be arranged by the Office of Scientific Integrity.

In the opinion of the Panel, this situation fits the stated requirements to proceed from the Inquiry Phase to a Formal Investigation. In this regard, you should charge the Panel as to its role in the formal investigation, for example whether the Panel should interview certain persons who participated in data collection and analysis. The Panel recommends that you proceed with a formal investigation and that you define the role of the Panel and the current Inquiry Team in that investigation.

Sincerely,

Howard E. Morgan, M.D. Senior Vice President for Research

Acting for
Frederic M. Richards,
Chairman
Sterling Professor of
Molecular Biophysics and

Biochemistry, Yale University

HEM:dmm

#X!

wy23

JUL 2 3 1990

Howard E. Morgan, M.D. Senior Vice President for Research Weis Center for Research Geisinger Clinic North Academy Avenue Danville, Pennsylvania 17822-2601

Dear Dr. Morgan:

This is in response to your letter of June 29 written on behalf of the Panel of Consultants and recommending that the National Institutes of Health (NIH) inquiry into research conducted in the laboratory of Dr. Robert Gallo be redesignated as an investigation.

I have given considerable thought to the recommendation both because of my high regard for the Panelists and because of their uniquely important role toward ensuring the efficacy and objectivity of our process. Moreover, I recognize the sincerity and positive intent behind the proposal. Nevertheless, I conclude that redesignation now would be premature, although I conclude that redesignation now we next convene the Panel. At plan to discuss this matter when we next convene the Panel. At plan to discuss this matter when we next convene the following that time, we also can discuss the Panel's role. The following paragraphs explain why I believe that the recommended redesignation would do disservice to all concerned if effected now.

Part of my rationale relates to the process. Although I understand why many people might view our approach to the Gallo inquiry as having the complexity and labor intensiveness one inquiry finds in an investigation, the activity to date still normally finds in an investigation, the activity to date still falls within what constitutes an Office of Scientific Integrity (OSI) inquiry. In fact, several other OSI cases have been of (OSI) inquiry. In fact, several other OSI cases have been of similar character. In my judgment, a decision of the magnitude similar character. In my judgment, a decision of the magnitude of the one recommended must be based on substance rather than appearance.

The substantive part of my rationale relates to the absence from either your letter or OSI reports of any "substantial reason to believe scientific misconduct may have occurred." This quote from the charge to the Panel defines the threshold for transformation from inquiry to investigation. I am concerned transformation of us could explain adequately why we should ignore the charge at this stage.

FILE COPY

| this s | stage. | | 1 2/25 | OFFICE | SURNAME | DATE |
|--------|-----------------|----------------|--------|--------|---------|------|
| OFFICE | SURNAME DATE | OFFICE SURNAME | DATE | | | |
| 7757 | Jacque 3/20/90 | | | | | |
| 100 | Janones - 7/20% | | | | | |
| ب عارب | | | | | | |

Page 2 - Howard E. Morgan, M.D.

The OSI staff has informed me that the inquiry is in an especially significant phase. They expect to receive soon Dr. Gallo's response to the detailed set of Panel-endorsed questions about the four papers published in Science in May 1984. His answer will be available for review at the next Panel meeting and those deliberations should leave us all better positioned with respect to whether we have reached the threshold for redesignating our probe.

I hope these comments are helpful. I will be pleased to discuss them by telephone with you and other representatives of the Panel in the near future if you wish and in any event look forward to the next Panel meeting.

sincerely yours,

/8/ William F. Raub, Ph.D.

William F. Raub, Ph.D. Acting Director

NIH/OD/OSI/S. Hadley/6/28/90/496-2624 Official Files Located Bldg. 31 Room BlC39